Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Clinical trial NCT02940301 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02940301
- Sponsor
- Ohio State University Comprehensive Cancer Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-12-20
- Primary completion
- 2026-08-15
- Enrollment
- 18
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.